Immunocore Holdings plc
No SEC Form 4 filings for $IMCR in the last 30 days.
Immunocore (NASDAQ:IMCR) reported Q2 updates on tebentafusp (KIMMTRAK). At AACR, it cited 5-year overall survival of 16% vs 8% in HLA-A*02:01-positive metastatic uveal melanoma. TEBE-AM enrollment nears 540; topline data expected end-2026. Q2 R&D was $74M, net loss just under $1M, cash $880M. Rebates expected ~$120M in H2 2026.
Immunocore Holdings (IMCR) reported Q2 2026 EPS of a loss of $0.02, wider than the Zacks Consensus loss of $0.01. Revenue rose 18.3% Y/Y to $115.9 million, beating the $114 million estimate, driven by Kimmtrak net product sales. Management cited about $6 million of US distributor inventory stocking as a Q3 headwind.
Immunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressrelease-q22026.htm EX-99.1 Document Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for pre
Over the past 7 days, alphai's AI scored 3 news stories mentioning IMCR (Immunocore Holdings plc). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent IMCR coverage spans financial news, earnings and technology.
Clinical progress in multiple melanoma programs plus updated cash and rebate outlook can shift risk perception ahead of late-2026 readouts.
Earnings miss is modest, but the disclosed Q3 headwind from distributor inventory stocking is a near-term demand signal for Kimmtrak.
The 8-K adds fresh operating datapoints (Q2 sales, cash balance, expected rebate accruals) plus time-sensitive clinical milestones that can move biotech sentiment and valuation.
Updated early clinical data for brenetafusp (including PD-1 resistance subgroup) supports the Phase 3 PRISM-MEL-301 rationale and can move biotech sentiment.
Updated efficacy/safety in heavily pretreated melanoma (including primary PD-1 resistance) supports the 160 mcg dose choice and strengthens the Phase 3 rationale.
alphai scores every news story that mentions IMCR with an AI model for sentiment and relevance, and aggregates insider trades from Immunocore Holdings plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Immunocore (NASDAQ:IMCR) reported Q2 updates on tebentafusp (KIMMTRAK). At AACR, it cited 5-year overall survival of 16% vs 8% in HLA-A*02:01-positive metastatic uveal melanoma. TEBE-AM enrollment nears 540; topline data expected end-2026. Q2 R&D was $74M, net loss just under $1M, cash $880M. Rebates expected ~$120M in H2 2026.
6 min readImmunocore Holdings (IMCR) reported Q2 2026 EPS of a loss of $0.02, wider than the Zacks Consensus loss of $0.01. Revenue rose 18.3% Y/Y to $115.9 million, beating the $114 million estimate, driven by Kimmtrak net product sales. Management cited about $6 million of US distributor inventory stocking as a Q3 headwind.
4 min readImmunocore Holdings plc (IMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressrelease-q22026.htm EX-99.1 Document Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM trial for pre
7 min readImmunocore Holdings (NASDAQ:IMCR) said May 31 it updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma, presented in a 2026 ASCO poster. The company reported a 6-month overall survival rate of 87% and a 52% disease control rate in HLA-A*02:01-positive patients, including those with primary PD-1 resistance, and reaffirmed Phase 3 PRISM-MEL-301 plans combining brenetafusp 160 mcg with nivolumab.
4 min readImmunocore reported updated Phase 1/2 brenetafusp data in heavily pretreated HLA-A*02:01-positive advanced melanoma at ASCO 2026. In 66 monotherapy patients, 6-month OS was 87% and disease control rate 52% (ORR 12%); median OS was 14.3 months. The company said results supported a 160 mcg dose for Phase 3 PRISM-MEL-301 and that safety was generally well tolerated.
5 min readImmunocore Holdings Plc has filed to sell 69,271 ADRs through a same-day cashless exercise and sale scheduled for May 26, 2026, with cash settlement brokered by J.P. Morgan Securities LLC. The filing also details recent sales by David Berman, including 11,832 ADRs sold on March 11, 2026, 25,000 on April 8, 2026, and 65,000 on May 21, 2026. The transaction is reported as having a neutral filing impact and sentiment, outlining key figures and definitions related to the Form 144 filing process.
3 min readImmunocore Holdings plc (IMCR) reported a profitable Q1 2026 with revenues of US$106.68 million and net income of US$12.97 million, alongside a US$76.48 million shelf registration for shares linked to its employee share ownership plan. This marked a shift to profitability after a loss in 2025 and indicates the company's focus on balancing growth, employee incentives, and capital access. The article suggests investors will now focus on the sustainability of this profitability and the ongoing clinical and commercial progress of KIMMTRAK, the company's main revenue driver, amidst rising R&D spending.
4 min readSingle ascending dose data show IMC-I109V has manageable safety profile and antiviral activity ...
2 min readAlthough the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 min readImmunocore reports third quarter financial results and provides a business update KIMMTRAK® ( tebentafusp-tebn ) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026
3 min read
